A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia

• Published in: Cancer chemotherapy and pharmacology 1999, Vol.43 (2), p.141-144
• Main Authors: BERNSTEIN, S. H, FAY, J, FRANKEL, S, CHRISTIANSEN, N, BAER, M. R, JACOBS, C, BLOSCH, C, HANNA, R, HERZIG, G
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic agents; Biological and medical sciences; Chemotherapy; Humans; Immunoglobulin G - blood; Injections, Intravenous; Injections, Subcutaneous; Interleukin-1 - blood; Interleukin-6 - blood; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - metabolism; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Receptors, Interleukin-1 - administration & dosage; Receptors, Interleukin-1 - immunology; Receptors, Interleukin-1 - metabolism; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - immunology; Recombinant Proteins - pharmacokinetics; Recurrence; Treatment Outcome; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s002800050874

The recombinant human interleukin-1 receptor (rhu IL-1R) is a soluble truncated form of the type 1 full-length membrane-bound receptor that binds IL-1 with identical affinity to that of the membrane form. As such, it may have clinical potential by sequestering IL-1, thereby preventing it from binding to its membrane-bound receptor and eliciting a biological effect. As IL-1 has been shown to regulate leukemic cell proliferation in an autocrine fashion, a phase I trial of rhu IL-1R was conducted in patients with relapsed and refractory acute myeloid leukemia (AML). The study group comprised 11 patients who were sequentially treated on one of three dose levels, receiving a single intravenous (i.v.) bolus dose on day 1 followed by 13 days of daily subcutaneous (s.c.) injections with the option of an additional 14 days of treatment if a response of stable disease or better was achieved. Dose level 1 i.v. bolus 500 microg/m2, s.c. dose 250 microg/m2 per day (five patients); dose level 2 i.v. bolus 1000 microg/m2, s.c. dose 500 microg/m2 per day (three patients); dose level 3 i.v. bolus 2000 microg/m2, s.c. dose 1000 microg/m2 per day (three patients). Owing to limited drug availability, the study was designed to only examine these three dose levels. rhu IL-IR was well tolerated. There was no grade 3 or 4 non-hematological toxicity related to the study drug and the maximum tolerated dose was not reached. No IL-1R-blocking antibodies developed during the course of the study. Serum levels of IL-1beta, IL-6 and TNF were undetectable before, during and after rhu IL-IR administration. The terminal half-life after i.v. dosing was at least 7-12 h, and after s.c. dosing 2-4 days. Serum levels of rhu IL-1R up to 360- and 25-fold those of pretreatment levels were achieved after i.v. and s.c. dosing respectively. No patient had a complete, partial or minor response to treatment; four had stable disease and seven had progressive disease. rhu IL-1R therapy was safe but did not have any apparent antileukemic effect at the doses administered.